Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard G Moore

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 3, 2022
HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancerAlexandra Samborski, M Craig Miller, Alexandra Blackman, et al.
Chemical Biology & Drug Design|October 7, 2011
Cytotoxic properties of Adamantyl isothiocyanate and potential in vivo metabolite adamantyl-N-acetylcystein in gynecological cancer cellsThilo S Lange, Timothy C Horan, Kyu K Kim, et al.
Gynecologic Oncology|March 18, 2014
Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy aloneKatina Robison, Dario Roque, Carolyn McCourt, et al.
Translational Oncology|May 15, 2019
Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian CancerRachael B Rowswell-Turner, Jennifer A Rutishauser, Kyu Kwang Kim, et al.
Gynecologic Oncology|December 3, 2014
Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancerRichard G Moore, Douglas M Hawkins, M Craig Miller, et al.
Gynecologic Oncology|August 2, 2011
Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell linesLaurent Brard, Thilo S Lange, Katina Robison, et al.
Gynecologic Oncology|May 23, 2008
Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusRichard G Moore, Amy K Brown, M Craig Miller, et al.
Gynecologic Oncology|May 29, 2007
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragmentDonna Badgwell, Zhen Lu, Laurence Cole, et al.
Frontiers in Oncology|February 7, 2018
Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer <i>via</i> Regulation of the Extracelluar MatrixJennifer R Ribeiro, Hilary M Gaudet, Mehreen Khan, et al.
Plos One|December 2, 2024
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancerKyukwang Kim, Negar Khazan, Jamie L McDowell, et al.
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 3, 2022
HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancerAlexandra Samborski, M Craig Miller, Alexandra Blackman, et al.
Chemical Biology & Drug Design|October 7, 2011
Cytotoxic properties of Adamantyl isothiocyanate and potential in vivo metabolite adamantyl-N-acetylcystein in gynecological cancer cellsThilo S Lange, Timothy C Horan, Kyu K Kim, et al.
Gynecologic Oncology|March 18, 2014
Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy aloneKatina Robison, Dario Roque, Carolyn McCourt, et al.
Translational Oncology|May 15, 2019
Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian CancerRachael B Rowswell-Turner, Jennifer A Rutishauser, Kyu Kwang Kim, et al.
Gynecologic Oncology|December 3, 2014
Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancerRichard G Moore, Douglas M Hawkins, M Craig Miller, et al.
Gynecologic Oncology|August 2, 2011
Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell linesLaurent Brard, Thilo S Lange, Katina Robison, et al.
Gynecologic Oncology|May 23, 2008
Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusRichard G Moore, Amy K Brown, M Craig Miller, et al.
Gynecologic Oncology|May 29, 2007
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragmentDonna Badgwell, Zhen Lu, Laurence Cole, et al.
Frontiers in Oncology|February 7, 2018
Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer <i>via</i> Regulation of the Extracelluar MatrixJennifer R Ribeiro, Hilary M Gaudet, Mehreen Khan, et al.
Plos One|December 2, 2024
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancerKyukwang Kim, Negar Khazan, Jamie L McDowell, et al.
Pageof 12